Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Denosumab Recombinant Human Monoclonal Antibody

Human Recombinant Monoclonal Antibody

Supplier:  Invitrogen™ MA541845

Catalog No. PIMA541845


Only null left
Add to Cart
This item is not returnable. View return policy

Description

Description

Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.

Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and 2 light chains. Each light chain consists of 215 amino acids. Each heavy chain consists of 448 amino acids with 4 intramolecular disulfides. FDA approved on June 1, 2010.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Denosumab
Recombinant Monoclonal
Unconjugated
AMG162; Prolia
Human TNFSF11/CD254.
100 μg
Primary
-20°C, Avoid Freeze/Thaw Cycles
Liquid
Chemical
ELISA, SDS-Page
1.73 mg/mL
PBS with no preservative; pH 7.4
Human
Protein A
RUO
Human
Antibody
IgG2 κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.